HALF YEAR RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 2025

20 MAY 2025

STRONG H1 PERFORMANCE FULL YEAR UPGRADE

DIPLOMA PLC VALUE-ADD SOLUTIONS



AGENDA

01 OVERVIEW

02 FINANCIAL PERFORMANCE

03 STRATEGY AND BUSINESS REVIEW

OVERVIEW

DIPLOMA PLC





- Organic growth of 9%, demonstrating quality of portfolio
- Balancing ambition with discipline: EPS up 23%, return on capital¹ of 19.1%
- Healthy acquisition pipeline: executed with discipline
- Diversified portfolio and differentiated business model: underpin confidence despite uncertainty
- Strong start to H2

Very strong performance. Full year upgrade

¹ Return on Adjusted Trading Capital Employed (ROATCE)



STRONG H1 PERFORMANCE

Organic revenue growth	Revenue growth	Adjusted operating profit margin	Adjusted EPS growth
9%	14%	21.5%	23%
H1 24: 5%	н1 24: 10%	H1 24: 19.6%	н1 24: 10%
Free cash flow conversion	Return on capital ¹	Leverage	Dividend growth
78 %	19.1%	1.1x	5%
н1 24: 76%	н1 24: 18.0%	H1 24: 0.9x	ні 24: 5%

Ambition with discipline



PEOPLE AND CULTURE



01 OVERVIEW

FINANCIAL PERFORMANCE


02

DIPLOMA PLC



REVENUE GROWTH

Six months ended 31 March




Very strong organic growth



OPERATING MARGIN EXPANSION

Six months ended 31 March




All profit metrics are adjusted and stated before acquisition related and other charges and acquisition related finance charges



COMPOUNDING EPS GROWTH

Six months ended 31 March




Continuing long-term track record

All profit metrics are adjusted and stated before acquisition related and other charges and acquisition related finance charges




STRONG CASH CONVERSION

Six months ended 31 March





DISCIPLINED STEWARDSHIP OF CAPITAL




High teens returns




WELL-POSITIONED AGAINST TARIFF BACKDROP

US businesses 52% of Group revenue US sourced US generated revenue >80%

Non-US businesses 48% of Group revenue





RESILIENT MODEL

- Diversified portfolio
- Value-added solutions
- Low cost, critical components
- 'Local for local' supply chains

MITIGATING ACTIONS

- Proactive customer engagement
- Confident pricing
- Selective re-sourcing



UPGRADING FY25 GUIDANCE

Confidence in our model Consistent delivery

Strong first half performance

Momentum into H2 across all Sectors Organic revenue growth 8% (up from 6%)

Operating margin C.22% (up from c.21%)

Net acquisition revenue growth 2% (unchanged)

Positive outlook


STRATEGY AND BUSINESS REVIEW

03

DIPLOMA PLC




A CLEAR STRATEGY FOR GROWTH





SUSTAINABLE QUALITY COMPOUNDING: AMBITIOUS ORGANIC GROWTH



GROWTH OPPORTUNITY

- Fantastic growth opportunities for all businesses
- Increasing exposure to structurally growing end markets
- Massive geographic/ product white space

EXECUTION: SALES EXCELLENCE

- Share of wallet: excellent customer service and relationships
- Building our business
 development capability
- Leveraging the Group network



SUSTAINABLE QUALITY COMPOUNDING: DISCIPLINED RETURNS

EFFECTIVE CAPITAL DEPLOYMENT

£2.0bn capital deployed



FY19-24

H1 25 return on capital: 19.1%

HEALTHY ACQUISITION PIPELINE

Average size Active Long term by enterprise value pipeline opportunities >3,500 >60 c.£25m (from >50 at FY24) (from >3.000 at FY24) (consistent with FY24) Well diversified (by number of opportunities) By sector By geography Seals N. America Europe Controls UK & Ireland Life Australia Sciences



SUSTAINABLE QUALITY COMPOUNDING: CONSISTENT DELIVERY

DIVERSIFIED PORTFOLIO

- Broad end-market exposure
- Attractive geographical footprint
- Diverse specialised product portfolio
- Agile businesses unconstrained by markets


DIFFERENTIATED BUSINESS MODELS

- Value-add solutions
- Low cost components funded from customers' opex
- Critical to customer needs in high-stakes applications
- Responsive customer service and deep technical support
- Local supply chains

Resilience through the cycle



CONTROLS: EXCELLENT PERFORMANCE



* Pro forma revenues adjusted for acquisitions and disposals completed during the period

	H1 25	H1 24	Change
Revenue	£391.3m	£288.1m	+36%
Organic growth	+16%	+7%	
Adjusted operating profit	£114.4m	£69.9m	+64%
Adjusted operating margin	29.2%	24.3%	+490bps

H125 highlights

- Windy City Wire: Double-digit growth. Diversified revenue growth
- International Controls: accelerated share gains in high growth end markets
- Continued outperformance in Peerless driving ROATCE > 20% in year one
- Portfolio discipline: one small disposal in the period
- Margin +490bps: accretive acquisition of Peerless
- Confidence in outlook



PEERLESS: A GREAT FIRST YEAR



STRONG AEROSPACE MARKET DEMAND

- New build backlog
- Active refurbishment

CRITICAL ROLE IN SUPPLY CHAIN

- Quality product/service
- Inventory availability

BRILLIANT TEAM

- Strong leadership
- Great culture

EXCELLENT PERFORMANCE

- Great first year
- Expect moderation to historic levels

Year one return on capital >20%



SEALS: RESILIENT PERFORMANCE

PERCENTAGE OF **GROUP REVENUE*** 31% SECTOR REVENUE MIX • 43% Seals 25% Gaskets 25% Hoses & fittings 7% Pumps & valves • 47% North America 23% United Kingdom 18% Europe 12% Australasia / other

* Pro forma revenues adjusted for acquisitions and disposals completed during the period

	H1 25	H1 24	Change
Revenue	£226.7m	£241.2m	(6%)
Organic growth	0%	+1%	
Adjusted operating profit	£42.4m	£44.3m	(4%)
Adjusted operating margin	18.7%	18.4%	+30bps


H125 highlight

- Continued resilience in challenging markets
- Sequential growth from Q1 to Q2
- North American Seals: Modest growth and sequential improvement
- International Seals: Pockets of growth mitigated impact of market softness
- Portfolio discipline: two disposals in Q1
- Margins +30bps: pricing, mix benefits, and cost discipline
- Sector well-positioned for future growth



LIFE SCIENCES: STRONG PERFORMANCE

PERCENTAGE OF GROUP REVENUE



	H1 25	H1 24	Change
Revenue	£110.5m	£109.0m	+1%
Organic growth	+6%	+5%	
Adjusted operating profit	£21.9m	£21.6m	+1%
Adjusted operating margin	19.8%	19.8%	_

H125 highlights


- Improving IVD and medtech markets
- Good development of new business pipeline
- Share gains in Australia and Canada driving strong growth
- Improving product portfolio in Europe
- Stable margin: product portfolio rationalisation in Europe and operating leverage offsetting selective scaling investments
- Positive outlook for the Sector



SUSTAINABLE QUALITY COMPOUNDING




- Very strong performance building on long-term track record
- Organic growth of 9%, demonstrating quality of portfolio
- Balancing ambition with discipline: EPS up 23%, return on capital¹ of 19.1%
- Healthy acquisition pipeline: executed with discipline
- Diversified portfolio and differentiated business model: underpin confidence despite uncertainty
- Strong start to H2. Upgrade to full year guidance.





145.8

OUR TRACK RECORD



FINANCIAL KPIS

Five-year trends

	5yr average	2024	2023	2022	2021	2020
Reported revenue growth	20% ¹	+14%	+19%	+29%	+46%	(1%)
Organic revenue growth	7%	+6%	+8%	+15%	+12%	(7%)
Adjusted operating margin	19%	20.9%	19.7%	18.9%	18.9%	16.2%
Adjusted EPS growth	18% ¹	+15%	+18%	+26%	+51%	(12%)
Free cash conversion	101%	101%	100%	90%	103%	113%
Return on capital ²	18%	19.1%	18.1%	17.3%	17.4%	19.1%
Leverage ratio ³	1.2x	1.3x	0.9x	1.4x	1.1x	n/a
Dividend growth	16%	5%	5%	26%	42%	3%

¹5-year CAGR

² Return on Adjusted Trading Capital Employed (ROATCE)


³Net debt / EBITDA







SIGNIFICANT "WHITE SPACE"







INCOME STATEMENT

Six months ended 31 March

£m	H1 25	H124	Change
Revenue	728.5	638.3	+14%
Adjusted operating profit	156.9	125.4	+25%
Operating margin (%)	21.5%	19.6%	
Financial expense, net	(14.1)	(10.2)	
Profit before tax	142.8	115.2	+24%
Effective tax rate	24.5%	24.0%	
Adjusted earnings	107.5	87.2	+23%
Weighted average no. shares (m)	134.1	134.0	
Adjusted earnings per share	80.2p	65.1p	+23%
Interim dividend per share	18.2p	17.3p	+5%



SECTOR REVENUE AND PROFIT

		Revenue		Organic	growth
	H1 25 £m	H124 £m	Change	 H125 %	H1:
Controls	391.3	288.1	+36%	+16	
Seals	226.7	241.2	(6%)	+0	
Life Sciences	110.5	109.0	+1%	+6	
Group	728.5	638.3	+14%	+9	

Adjuste	Adjust		
H1 25 £m	H124 £m	Change	H1 25 %
114.4	69.9	+64%	29.2
42.4	44.3	(4%)	18.7
21.9	21.6	+1%	19.8
(21.8)	(10.4)	(110%)	-
156.9	125.4	+25%	21.5

Adjusted operating margin			
H1 25 %	H124 %	Change	
29.2	24.3	+490bps	
18.7	18.4	+30bps	
19.8	19.8	+0bps	
-	-	-	
21.5	19.6	+190bps	

H124 %

+7

+1

+5

+5

Controls

Life Sciences

Central costs

Seals

Group

BALANCE SHEET

04 APPENDIX



£m, as at 31 March	H1 25	H124
Goodwill and acquisition intangible assets	1,039.3	919.6
Tangible and other intangible assets	62.0	62.5
Net lease liabilities	(3.7)	(6.6)
Net working capital	291.5	237.3
Trading capital employed - reported	1,389.1	1,212.8
ROATCE	19.1%	18.0%
Retirement benefit assets, net	1.6	1.1
Acquisition liabilities and assets, net	(23.4)	(20.9)
Net debt	(373.5)	(258.6)
Minority interests and deferred tax, net	(49.6)	(60.4)
Total shareholders' equity (excluding minority interests)	944.2	874.0


AMPLE CAPACITY FOR GROWTH

• £555m RCF

04

- USPPs: €250m + \$150m
- c.£500m cash and undrawn facilities at 31 March
- All-in blended rate @ 5.3%¹
- Average maturity of drawn debt 7.4 years
- Covenants: leverage <3.5x, interest cover >4.0x
- Pension buy-in completed

¹ Weighted average rates



Funding facilities (fm)

